Portfolio company
KyDo Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
KyDo
This biotechnology company develops small molecule inhibitors for the treatment of cancer variants in oncology patients.
Accent Therapeutics
This biopharmaceutical company develops small molecule precision therapies for patients with various types of cancer.
HYKU Biosciences
This biotechnology company develops precision covalent small-molecule medicines targeting disease-driving proteins to treat patients with cancer and other illnesses.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
AdoRx Therapeutics
This company develops small-molecule adenosine receptor antagonists for pharmaceutical partners to treat cancer by disrupting immune evasion in the tumour microenvironment.
Kymera Therapeutics
This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.
Kinnate Biopharma
The company develops small molecule kinase inhibitors for patients with difficult-to-treat cancers featuring specific genetic alterations.